NCT04483778View on ClinicalTrials.gov

B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

July 13, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2040

Conditions
Pediatric Solid TumorGerm Cell TumorRetinoblastomaHepatoblastomaWilms TumorRhabdoid TumorCarcinomaOsteosarcomaEwing SarcomaRhabdomyosarcomaSynovial SarcomaClear Cell SarcomaMalignant Peripheral Nerve Sheath TumorsDesmoplastic Small Round Cell TumorSoft Tissue SarcomaNeuroblastomaMelanoma
Interventions
BIOLOGICAL

second generation 4-1BBζ B7H3-EGFRt-DHFR

Autologous CD4+ and CD8+ T-cells lentivirally transduced to express a second generation 4-1BBζ B7H3-EGFRt-DHFR

BIOLOGICAL

second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tG

Autologous CD4+ and CD8+ T-cells lentivirally transduced to express a second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tG

DRUG

Pembrolizumab

SCRI-CARB7H3(s)x19 plus pembrolizumab

Trial Locations (1)

98105

Seattle Children's Hospital, Seattle

All Listed Sponsors
lead

Seattle Children's Hospital

OTHER